Scarica l'app Stockscreener
1.2668
2.55%
-0.0332
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.30
Aprire:
$1.25
Volume 24 ore:
125.10K
Relative Volume:
0.05
Capitalizzazione di mercato:
$13.47M
Reddito:
-
Utile/perdita netta:
$-39.14M
Rapporto P/E:
-0.2122
EPS:
-5.97
Flusso di cassa netto:
$-28.20M
1 W Prestazione:
-1.03%
1M Prestazione:
-18.79%
6M Prestazione:
-53.08%
1 anno Prestazione:
-91.70%
Intervallo 1D:
$1.21
$1.287
Intervallo di 1 settimana:
$1.20
$1.36
Portata 52W:
$0.65
$17.00
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Nome
Citius Pharmaceuticals Inc
Settore
Industria
Telefono
(908) 967-6676
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Confronta CTXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.2668 | 13.97M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.59 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.96 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.31 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.35 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
301.83 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Citius Oncology Beats Q3 EPS Estimates with $0 Revenue - AInvest
Citius Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Oncology (CTOR) $9M Offering; Cash Runway Through Sept 2025 | TENKU SEC FilingForm 10-Q - Stock Titan
Citius Secures $21.5M Funding as Cancer Drug LYMPHIR Nears Q4 2025 Commercial Launch - Stock Titan
Why Citius Pharmaceuticals Inc. stock attracts strong analyst attention2x Return in 30 Days Picks - 한국정경신문
Citius Oncology Announces Pricing of $9.0 Million Public Offering - ADVFN Brasil
Chart overlay techniques for tracking Citius Pharmaceuticals Inc.Swing Trade Entry and Exit Point Analysis - Newser
Tools to assess Citius Pharmaceuticals Inc.’s risk profileVolume Spike Detection for Early Breakouts - Newser
Sector ETF performance correlation with Citius Pharmaceuticals Inc.Risk Shielded Trade Watch with Analysis - Newser
Is Citius Pharmaceuticals Inc. stock a growth or value playWeekly Breakout Forecast with Entry Zones - Newser
Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Monday - Defense World
Citius CTXR 2025Q3 Earnings Preview Upside Ahead on Potential New Product Launch - AInvest
Why Citius Pharmaceuticals Inc. is moving todaySummary of Reliable Long-Term Trade Models - Newser
Published on: 2025-08-04 16:39:39 - beatles.ru
Published on: 2025-08-04 09:23:45 - beatles.ru
What is the dividend policy of Citius Pharmaceuticals Inc. stockMaximize your gains with expert trading tips - Jammu Links News
When is Citius Pharmaceuticals Inc. stock expected to show significant growthSpectacular growth rates - Jammu Links News
What are Citius Pharmaceuticals Inc. company’s key revenue driversUnstoppable trading performance - Jammu Links News
What institutional investors are buying Citius Pharmaceuticals Inc. stockAchieve breakthrough investment performance - Jammu Links News
Is Citius Pharmaceuticals Inc. a good long term investmentExceptional ROI - Jammu Links News
Why is Citius Pharmaceuticals Inc. stock attracting strong analyst attentionExceptional trading performance - Jammu Links News
What makes Citius Pharmaceuticals Inc. stock price move sharplyTrack stocks with high upside potential easily - Jammu Links News
How many analysts rate Citius Pharmaceuticals Inc. as a “Buy”Accelerated investment success - Jammu Links News
How does Citius Pharmaceuticals Inc. compare to its industry peersFree Stock Watchlist For Fast Growth - Jammu Links News
What are the technical indicators suggesting about Citius Pharmaceuticals Inc.Chart Pattern Trend Scanner With Low Risk - Jammu Links News
What is Citius Pharmaceuticals Inc. company’s growth strategyRetirement Planning Review With Proven Results - Jammu Links News
Is Citius Pharmaceuticals Inc. reversing from oversold territoryIntraday Trend Analysis for Fast Gains Released - metal.it
Citius Pharmaceuticals Inc. Chart Enters High Volatility ZoneCommunity Entry Consensus Trade Ideas Shared - metal.it
Wyckoff Accumulation Phase Possible in Citius Pharmaceuticals Inc.Weekly Chart Analysis With Entry Advice Provided - metal.it
Is Citius Pharmaceuticals Inc. stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Is it the right time to buy Citius Pharmaceuticals Inc. stockBuild wealth steadily with expert advice - Jammu Links News
What is the risk reward ratio of investing in Citius Pharmaceuticals Inc. stockBreakout profit opportunities - Jammu Links News
What are analysts’ price targets for Citius Pharmaceuticals Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - Jammu Links News
How Citius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Signals - metal.it
What analysts say about Citius Pharmaceuticals Inc. stockFree Investment Community - printweek.in
Citius Pharmaceuticals Inc. Stock Analysis and ForecastLightning-fast growth - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - StreetInsider
What drives Citius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):